Neurology · 2009 · 76 citations · 18 references
MedicineNeurologyNeuroscienceCognitive NeuroscienceDementiaNeurodegenerationAlzheimer DiseaseBiomarkers Of NeurodegenerationCognitive ImpairmentDementia BiomarkersMagnetic Resonance SpectroscopyNeurodegenerative Diseases1D Proton Nuclear Magnetic Resonance SpectroscopyAlzheimer Disease DementiaCholine MetabolismMagnetic ResonanceMild Cognitive Impairment DiagnosisMulticenter Clinical TrialsNuclear Magnetic Resonance SpectroscopyTemporal Lobe Atrophy
OBJECTIVE: The need for biological markers of Alzheimer disease (AD) is constantly increasing. Proton magnetic resonance spectroscopy ((1)H-MRS) studies have provided consistent evidence for a reduction of the neuronal marker N-acetylaspartate (NAA) in patients with AD. Within the German Competence Network on Dementia, we conducted a (1)H-MRS study in patients with mild dementia and mild cognitive impairment (MCI) at four sites to investigate the multicenter feasibility of (1)H-MRS. METHODS: In total, 130 patients with dementia (98 AD, 32 non-AD), 136 subjects with MCI (70 of AD type, 66 of non-AD type), and 45 unimpaired control subjects were included. Single-volume (1)H-MRS of the left medial temporal lobe was performed at long and short echo times. Metabolites were quantified and metabolic ratios were determined. RESULTS: We found a significant reduction of NAA concentration in patients with AD as compared to healthy volunteers and compared to patients with MCI of AD type. NAA/Cr (creatine/phosphocreatine) was also lower in patients with AD compared to control subjects. NAA, choline compounds, and Cr were lower in patients with AD compared to patients with non-AD dementia. CONCLUSIONS: We demonstrated the multicenter feasibility of proton magnetic resonance spectroscopy ((1)H-MRS) of the medial temporal lobe in mild dementia and mild cognitive impairment, which is a prerequisite for the application of (1)H-MRS in large-scale clinical trials. Since the concentration measures of the metabolites are adjusted for brain tissue volume, these findings are indicators of biochemical pathology beyond brain atrophy.
18
Clinical diagnosis of Alzheimer's disease
Guy M. McKhann, David A. Drachman, Marshall Folstein et al. · Neurology · 1984 · 28K citations · Full text
<sup>1</sup> H MR spectroscopy in common dementias
Kejal Kantarci, Ronald C. Petersen, Bradley F. Boeve et al. · Neurology · 2004 · 264 citations
Medicine, Neurology, Neuroscience +11